Imaging software developer Mirada Medical and BTG are collaborating to develop dosimetry software for radioembolization therapy.
The companies are working together to provide a more personalized approach to radioembolization for liver cancer patients using BTG's TheraSphere, which delivers yttrium-90 via small microspheres.
Mirada and BTG plan to make the software available in 2016.